New law directs HHS to consider comparative effectiveness information as it approaches price negotiations with manufacturers. But it’s not clear what that means and stakeholders will watch for greater clarity from implementing regulations. ICER’s Steve Pearson weighs in on what they might say.
For the first time, a law enacted in the US authorizes the Health and Human Services Department to set drug...